Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12.

Conclusion: Ixekizumab provides a faster onset of effect and earlier clinical benefits than guselkumab, tildrakizumab, or risankizumab in patients with moderate-to-severe psoriasis, as reflected by higher levels of skin improvement than with these IL-23 p19 inhibitors up to week 12. PMID: 32299269 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32299269?dopt=Abstract

Source: Journal of Dermatological Treatment - April 19, 2020 Category: Dermatology Tags: J Dermatolog Treat Source Type: research